BCIQ Profiles

Company Profile Report
0512 ECP Wugen
BioCentury & Getty Images

Emerging Company Profile

Wugen: deploying memory NK cells against cancer

And turning allogeneic CAR T cells against T cell malignancies

With a license to a potent NK cell subtype and a body of clinical data, Wugen is advancing its memory NK cells to the clinic.

May 17, 2021 | 6:08 PM GMT

Wugen is adding a new subset of NK cells to the cell therapy toolkit with its memory NK cell approach, which may lead to high antitumor efficacy without requiring

Read the full 839 word article

How to gain access

Continue reading with a
two-week free trial.